Jefferies Starts Supernus Pharmaceuticals (SUPN) at Buy, $13 PT

Jefferies initiates coverage on Supernus Pharmaceuticals (NASDAQ: SUPN) with a Buy. PT $13.00.

The firm comments, "With two recently approved epilepsy drugs (each ~$250M peak), pipeline optionality and little binary risk, SUPN offers a compelling risk/reward with only ~$175M EV. Launch expectations have dropped precipitously and although consensus seems low on 2013 expenses, based on our conversations with high-prescribing neurologists, we think the Q1 launch of Oxtellar XR will be surprisingly strong, and drives our $13 target."

For an analyst ratings summary and ratings history on Supernus Pharmaceuticals click here. For more ratings news on Supernus Pharmaceuticals click here.

Shares of Supernus Pharmaceuticals closed at $7.48 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Raymond James Starts SpyGlass Pharma (SGP) at Outperform
• UBS Starts Schrodinger (SDGR) at Neutral
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'